Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Dermatologic 2CNS 2Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 91Carcinoma, Non-Small-Cell Lung 84Neoplasms 48Carcinoma, Renal Cell 44Neoplasm Metastasis 40Carcinoma, Hepatocellular 36Squamous Cell Carcinoma of Head and Neck 35Colorectal Neoplasms 31Pancreatic Neoplasms 24Lung Neoplasms 20Stomach Neoplasms 19Head and Neck Neoplasms 18Carcinoma, Transitional Cell 17Hodgkin Disease 16Breast Neoplasms 16Small Cell Lung Carcinoma 15Ovarian Neoplasms 14Urinary Bladder Neoplasms 13Recurrence 13Advanced Cancer 13Glioblastoma 12Brain Neoplasms 12Lymphoma 11Kidney Neoplasms 11Glioma 11Prostatic Neoplasms 10Lymphoma, Non-Hodgkin 10Uveal Melanoma 9Triple Negative Breast Neoplasms 9Sarcoma 9

Interventions

Irinotecan 13Cyclophosphamide 11Vincristine 10Filgrastim 10Radiotherapy 9Ifosfamide 9Doxorubicin 9Dactinomycin 7Melphalan 6Granulocyte Colony-Stimulating Factor 6Etoposide 6cixutumumab 5Sirolimus 5Peripheral Blood Stem Cell Transplantation 5pegfilgrastim 4Topotecan 4Temozolomide 4Radiation 4Gemcitabine 4Busulfan 4temsirolimus 3sargramostim 3Granulocyte-Macrophage Colony-Stimulating Factor 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3trioctyl phosphine oxide 2regorafenib 2olaparib 2etoposide phosphate 2eribulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Rhabdomyosarcoma × Nivolumab × Clear all
NCT05302921 2025-01-01

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Children's National Research Institute

Phase 2 Completed
5 enrolled
CNSDermatologicGastrointestinalGenitourinarySarcoma

Carcinoma, Hepatocellular, Melanoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

National Cancer Institute (NCI)

Phase 1/2 Completed
140 enrolled 23 charts
CNSDermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡